7
Participants
Start Date
October 5, 2007
Primary Completion Date
May 12, 2011
Study Completion Date
May 12, 2011
Erlotinib
Tarceva single agent therapy: 150 mg/day PO
5-fluorouracil
5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
Leucovorin
400 mg/m2 IV once every 2 weeks for 16 weeks
Oxaliplatin
85 mg/m2 IV once every 2 weeks for 16 weeks
University of California, San Francisco, San Francisco
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of California, San Francisco
OTHER